Haemonetics Corporation (HAE)

Debt-to-equity ratio

		Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020
Long-term debt	US$ in thousands	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Total stockholders’ equity	US$ in thousands	951,605	906,860	878,851	905,368	959,959	943,319	893,660	864,616	817,997	775,979	729,009	770,423	749,424	730,775	698,549	677,080	731,670	719,152	667,923	608,569
Debt-to-equity ratio		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

March 31, 2025 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $951,605K
= 0.00

Haemonetics Corporation has consistently maintained a debt-to-equity ratio of 0.00 across all reported periods from June 30, 2020, to March 31, 2025. This indicates that the company has not utilized any debt to finance its operations and investments, relying solely on equity financing. A debt-to-equity ratio of 0.00 signifies a conservative financial structure, as there is no debt present to potentially amplify returns or risks. Investors may view this as a positive indicator of financial stability and solvency, as the absence of debt obligations may reduce financial risk and interest expenses. However, it is important to consider that a low or zero debt-to-equity ratio may also indicate missed opportunities for leveraging debt to potentially increase returns on equity. Overall, the consistent zero debt-to-equity ratio suggests Haemonetics Corporation's cautious approach to capital structure and financing activities.